The Good, The Bad, and The Ugly: Quality Data in Basic Research

Reproducibility and robustness of research data are the pillars of the scientific method.  However, reproducibility and robustness of published data in research is considered low.  This has raised major concerns among industrial and academic scientists, editors, publishers and funding organizations.  As a scientific community, there is a shared responsibility to address and resolve this issue.  Dr. Steckler discussed the factors underlying the lack of reproducibility and addressed ways to improve data reproducibility, robustness and data quality using a forward-looking approach. 

Webinar originally hosted Wednesday, January 27, 2016, at 12 noon ET.

Learn More

Webinar originally hosted Wednesday, January 27, 2016, at 12 noon ET
Watch Webinar

About Thomas Steckler, MD

Thomas Steckler graduated in Medicine in 1990 and obtained his MD in 1992 from the Free University of Berlin, Germany in collaboration with Schering AG.  He then moved to the MRC Neurochemical Pathology Unit in Newcastle, United Kingdom, became group leader at the Max Planck Institute for Psychiatry in Munich in 1997 and habilitated in 2006 in Biological Psychology at the Heinrich-Heine University, Düsseldorf, Germany.

In 2000, Dr. Steckler joined the Neuroscience Drug Discovery group of Janssen R&D, where he held various roles over the last 15 years.  He has an interest in quality systems, experimental design and analysis that will improve the rigor, reproducibility and utility in non-regulated research.  In 2015, Dr. Steckler moved to the Bioresearch Quality organization of Janssen.

Dr. Steckler has published numerous peer reviewed scientific articles and book chapters in the areas of cognition, stress, schizophrenia, autism and mood disorders, is the principal editor of Psychopharmacology, a member of several editorial boards, and is very active in international neuroscience societies and quality research consortia. 

More Webinars

The Power of Genetics in Predicting & Treating PTSD
Advancing our understanding of neuroinflammation: Driving a systems biology approach to re-classify brain disease
Demystifying Ontologies and Their Utility for Biomedicine
Showing Slide 1 of 4
Cohen Veterans Bioscience - Advancing Brain Health

An important message from CVB

From 2015–2024, Cohen Veterans Bioscience pioneered a new approach to researching PTSD and TBI.

CVB ceased operations in 2024.

This website is available for informational purposes only, providing details about our history and legacy.